A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)

Annals of Oncology ◽

10.1093/annonc/mdx371.050 ◽

2017 ◽

Vol 28 ◽

pp. v317-v318 ◽

Author(s):

D.F. McDermott ◽

R.W. Joseph ◽

T. Ho ◽

U. Vaishampayan ◽

S. Ali ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Finding ◽

Advanced Renal Cell Carcinoma ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)

10.1158/1535-7163.targ-17-b201 ◽

2018 ◽

Author(s):

Michael Atkins ◽

Richard Joseph ◽

Thai Ho ◽

Ulka Vaishampayan ◽

Sarah Ali ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase 1 ◽

Dose Finding ◽

Advanced Renal Cell Carcinoma ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma

Annals of Oncology ◽

10.1093/annonc/mdw373.03 ◽

2016 ◽

Vol 27 ◽

pp. vi266 ◽

Author(s):

J. Larkin ◽

B.I. Rini ◽

P. Nathan ◽

F. Thistlethwaite ◽

M. Gordon ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Finding ◽

Advanced Renal Cell Carcinoma ◽

Finding Study ◽

Treatment Naïve ◽

Phase 1B ◽

Dose Finding Study

Download Full-text

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p353 ◽

2015 ◽

Vol 3 (S2) ◽

Author(s):

Michael B Atkins ◽

Shilpa Gupta ◽

Toni K Choueiri ◽

David F McDermott ◽

Igor Puzanov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Finding ◽

Advanced Renal Cell Carcinoma ◽

Phase Ib ◽

Finding Study ◽

Treatment Naïve ◽

Dose Finding Study

Download Full-text

4520 POSTER Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71151-5 ◽

2007 ◽

Vol 5 (4) ◽

pp. 305

Author(s):

G.V. Kondagunta ◽

G. Hudes ◽

R. Figlin ◽

G. Wilding ◽

S. Hariharan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Interferon Alfa ◽

Dose Finding ◽

Line Treatment ◽

Finding Study ◽

Dose Finding Study ◽

First Line Treatment

Download Full-text

1305: Zoledronic Acid Reduces Long-Term Risk of Skeletal Complications in Patients with Advanced Renal Cell Carcinoma or Bladder Cancer

The Journal of Urology ◽

10.1016/s0022-5347(18)31519-2 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 429-430 ◽

Author(s):

Peter F. Mulders ◽

Kurt Miller ◽

N. Simon Tchekmedyian

Keyword(s):

Renal Cell Carcinoma ◽

Bladder Cancer ◽

Zoledronic Acid ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Skeletal Complications

Download Full-text

Sunitinib Superior to Interferon-α For Advanced Renal Cell Carcinoma

Internal Medicine News ◽

10.1016/s1097-8690(06)74366-9 ◽

2006 ◽

Vol 39 (20) ◽

pp. 35

Author(s):

FRAN LOWRY

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma

Case Medical Research ◽

10.31525/fda1-ucm636395.htm ◽

2019 ◽

Author(s):

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma

Download Full-text

Faculty Opinions recommendation of Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119981.576105 ◽

2008 ◽

Author(s):

Sharokh Shariat ◽

Jose Karam

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Interferon Alfa ◽

Advanced Renal Cell Carcinoma

Download Full-text

Faculty Opinions recommendation of Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1147883.604974 ◽

2009 ◽

Author(s):

Keith Flaherty ◽

Stephen Keefe

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Primary Tumor ◽

Advanced Renal Cell Carcinoma

Download Full-text

Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13484037.14861147 ◽

2012 ◽

Author(s):

Thomas Powles

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text